Study design
CPS
Key aspects of the methodology used in the OlympiA clinical trial (NCT02032823) will be summarized here, having been described in detail previously [OlympiA is an ongoing, prospective, multicenter, multinational, double-blind, randomized, phase 3 clinical trial with an expected overall follow-up of 10 years. Enrolled patients had gPatients with hormone receptor-positive eBC were considered high risk if they had at least four pathologically confirmed positive lymph nodes at initial surgery prior to ACT or had evidence of lack of pathological complete response (non-pCR) to NACT with a score of at least 3 for the CPS + EG staging system [